Altered Peptide Ligands: Redesigning Peptides for Tolerance

Peptide Autoimmune Therapy

1 amino acid change

A single amino acid substitution in a self-antigen peptide can convert it from a trigger of autoimmune attack into a signal for immune tolerance, redirecting T cells from inflammation to regulation.

Nicholson et al., Immunity, 1995

Nicholson et al., Immunity, 1995

View as image

The immune system destroys what it recognizes as foreign. In autoimmune disease, that targeting goes wrong: T cells attack the body's own tissues because they mistake self-proteins for threats. The conventional approach to treating autoimmune disease involves broad immunosuppression, which controls symptoms but also suppresses the immune responses that protect against infection and cancer. Altered peptide ligands (APLs) represent a fundamentally different strategy: instead of suppressing the entire immune system, redesign the peptide that triggers the attack so it teaches the immune system tolerance instead. For an overview of how this fits into the broader landscape, see peptide therapies for autoimmune disease: teaching tolerance.

APLs are synthetic variants of self-antigen peptides with one or a few amino acid substitutions at positions that contact the T cell receptor (TCR). These modifications change how the TCR interprets the signal, converting what was an inflammatory activation signal into a tolerogenic or regulatory one. The concept emerged from basic immunology research in the 1990s and reached clinical trials for multiple sclerosis and type 1 diabetes, where it produced both striking proof-of-concept data and serious safety setbacks.

How Altered Peptide Ligands Work

T cell activation requires a peptide antigen to be presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells (APCs). The T cell receptor (TCR) binds the peptide-MHC complex, and the quality of that interaction determines the outcome: strong binding to the native peptide produces full T cell activation, while altered binding can produce partial activation, anergy (functional unresponsiveness), or immune deviation (shifting T cells from inflammatory to regulatory phenotypes).

APLs exploit this by modifying the amino acids at TCR contact residues while preserving the amino acids that anchor the peptide to the MHC groove. The result is a peptide that still binds MHC and is presented to T cells, but that delivers a qualitatively different signal through the TCR. Depending on which amino acid is changed and what it is changed to, the outcome can range from partial agonism (reduced but not absent activation) to antagonism (active blockade of T cell function) to immune deviation (redirecting the T cell from a Th1 inflammatory response to a Th2 anti-inflammatory response).

Yu et al. (2023) reviewed the broader therapeutic potential of tolerance-based peptide vaccines in autoimmune diseases, categorizing the strategies as APLs, soluble peptide-MHC complexes, peptide-loaded tolerogenic dendritic cells, and peptide-conjugated nanoparticles.^[1] Each approach aims to present self-antigen in a context that promotes tolerance rather than immunity, but APLs are the only strategy that modifies the peptide itself.

The Proof of Concept: Preventing Autoimmune Encephalomyelitis

Nicholson et al. (1995) provided the foundational evidence that a single amino acid substitution in a self-antigen peptide could prevent autoimmune disease in an animal model.^[2] Working with experimental autoimmune encephalomyelitis (EAE), the standard animal model for multiple sclerosis, they identified tryptophan at position 144 of the myelin proteolipid protein (PLP) peptide 139-151 as the primary TCR contact point for disease-causing T cells.

By substituting glutamine for tryptophan at position 144 (creating the Q144 APL), they generated a peptide that prevented EAE development. The mechanism was immune deviation: the APL induced T cells that were cross-reactive with the native peptide but that produced anti-inflammatory cytokines (IL-4 and IL-10, characteristic of Th2 and Th0 responses) instead of the pro-inflammatory IFN-gamma characteristic of the Th1 response that drives disease. The APL did not simply fail to activate T cells; it actively redirected them toward a regulatory phenotype that could suppress the disease-causing Th1 response.

This study established three principles that defined the field: first, that TCR contact residues can be surgically modified without destroying peptide-MHC binding; second, that the quality of TCR signaling (not just its presence or absence) determines whether an immune response promotes disease or tolerance; and third, that immune deviation induced by APLs can protect against autoimmunity.

Clinical Trials in Multiple Sclerosis: Promise and Peril

The animal data was compelling enough to advance APLs into human clinical trials for multiple sclerosis. Two parallel phase II trials tested APLs based on myelin basic protein (MBP) peptide 83-99, one of the candidate autoantigens in MS. The results demonstrated both the potential and the danger of this approach.

Kappos et al. (2000) conducted a randomized, placebo-controlled trial of an MBP-derived APL in patients with relapsing MS.^[3] The trial was suspended by the safety board because 9% of patients developed hypersensitivity reactions. However, there were no increases in clinical relapses or new brain lesions in any patient, including those who experienced hypersensitivity. The immunological findings were remarkable: a 4- to 16-week course of APL therapy induced a persistent shift in the T cell response that lasted 2 to 4.5 years after treatment. T cells responsive to both the APL and the native MBP peptide switched from producing IFN-gamma (Th1/inflammatory) to producing IL-5 (Th2/anti-inflammatory). This demonstrated that APLs can produce lasting immune deviation in humans, not just transient suppression.

Bielekova et al. (2000) tested a different MBP-derived APL (CGP77116) in a separate phase II trial with MRI monitoring.^[4] This trial was halted for a more alarming reason: three patients developed MS exacerbations, and in two cases immunological studies linked the exacerbation directly to the APL treatment. The APL had activated, rather than tolerized, a subset of autoreactive T cells recognizing the native MBP peptide. These data revealed a fundamental challenge: the same APL can induce tolerance in some patients and trigger disease in others, depending on their individual T cell repertoire and immune context.

Together, these trials showed that APLs work in humans (the Kappos trial demonstrated years-long immune deviation) but that predicting which patients will tolerate and which will be harmed remains unsolved. This unpredictability largely stalled the clinical development of simple APL approaches for MS. For how other peptide immunotherapy approaches for multiple sclerosis have evolved since then, that article covers the next generation of strategies.

Beyond APLs: Next-Generation Tolerogenic Peptide Strategies

The safety issues with direct APL administration prompted the development of more controlled delivery strategies. Urbonaviciute et al. (2023) demonstrated a sophisticated approach: instead of administering the modified peptide alone, they loaded it onto recombinant MHC class II molecules to create a defined peptide-MHC complex that directly engages the TCR.^[5] Using a galactosylated collagen type II peptide bound to the mouse MHC molecule Aq, they showed that the complex expanded a population of VISTA-positive regulatory T cells and produced dominant tolerance that prevented autoimmune arthritis.

This approach addresses several limitations of free APL administration. By presenting the peptide already bound to MHC, the interaction with the TCR is more controlled and predictable. The MHC molecule can also be engineered to carry modifications (like the positively charged tag used by Urbonaviciute et al.) that direct the complex to specific T cell populations. The regulatory T cells expanded by this approach actively suppressed the autoimmune response, rather than merely deviating it from Th1 to Th2.

Other next-generation approaches include peptide-coupled nanoparticles (which deliver self-antigen to antigen-presenting cells in a tolerogenic context), peptide-loaded tolerogenic dendritic cells (which present self-antigen while also producing anti-inflammatory signals), and soluble peptide arrays (which present multiple epitopes simultaneously to address the heterogeneity of autoimmune T cell responses). All share the fundamental APL insight that the context of peptide presentation determines whether it triggers immunity or tolerance.

Applications Across Autoimmune Diseases

The APL concept is not limited to multiple sclerosis. Peptide approaches to type 1 diabetes prevention have explored modified insulin peptides to tolerize the T cells that destroy pancreatic beta cells. The NBI-6024 APL, based on an insulin B-chain peptide with amino acid substitutions at TCR contact residues, reached phase II trials for new-onset type 1 diabetes. While the trial did not show a clinical effect on beta-cell preservation, it demonstrated the feasibility of APL therapy in an autoimmune disease where the target antigen is known.

Peptide research in lupus (SLE) faces a more complex challenge because multiple autoantigens drive the disease. Tolerogenic peptides more broadly encompass any peptide strategy that induces tolerance, including unmodified self-peptides administered in tolerogenic contexts (oral tolerance, subcutaneous desensitization, nanoparticle delivery) as well as the modified sequences that define APLs specifically.

Rheumatoid arthritis represents a particularly promising target because the autoantigens (collagen type II epitopes) are well characterized and the joint inflammation is driven by identifiable T cell populations. The Urbonaviciute et al. study using MHC-collagen peptide complexes demonstrated complete protection against autoimmune arthritis in mice, with regulatory T cell expansion that actively suppressed disease rather than merely deviating the cytokine response.

The immune modulating peptide thymosin alpha-1 works through a different mechanism entirely, enhancing rather than suppressing immune function, but its ability to promote regulatory T cell expansion has generated interest in whether it could complement APL-based tolerance strategies.

What the Evidence Does and Does Not Support

The APL concept is well validated at the mechanistic level. Animal studies consistently show that single amino acid substitutions at TCR contact residues can convert disease-inducing peptides into tolerogenic ones. The Kappos et al. trial showed that APL-induced immune deviation can persist for years in humans. The Urbonaviciute et al. study demonstrates that next-generation delivery strategies can expand true regulatory T cells, not just shift cytokine profiles.

What remains unresolved is the safety margin. The Bielekova et al. trial showed that APLs can activate disease in some individuals while tolerizing others, and predicting who will respond which way requires understanding of individual TCR repertoires that current clinical tools cannot provide. No APL product has been approved for any autoimmune indication. The field has shifted toward approaches that add layers of control: presenting peptides on tolerogenic carriers, engineering MHC-peptide complexes, or using nanoparticle platforms that bias antigen-presenting cell behavior toward tolerance.

The 5-10% of the global population affected by autoimmune diseases still lacks disease-modifying therapies that address root cause rather than symptoms. Current treatments (corticosteroids, biologics like anti-TNF antibodies, JAK inhibitors) all operate through broad immunosuppression, increasing infection risk and reducing cancer immunosurveillance. APLs opened a conceptual door that next-generation peptide tolerance strategies are now walking through, with at least four distinct delivery platforms in preclinical or early clinical development as of 2023. The defining question for the field is not whether peptide-specific tolerance is achievable (the Kappos trial proved it is in humans) but whether it can be made safe and predictable enough for routine clinical use.

The Bottom Line

Altered peptide ligands are synthetic variants of self-antigen peptides designed to redirect T cell responses from inflammatory to tolerogenic. Animal studies demonstrated that a single amino acid change can prevent autoimmune disease, and a human MS trial showed APL-induced immune deviation lasting years. However, a parallel trial revealed unpredictable disease activation in some patients, stalling direct APL development. Next-generation approaches using MHC-peptide complexes, nanoparticles, and tolerogenic dendritic cells are building on the APL concept with improved safety control.

Frequently Asked Questions

What are altered peptide ligands?

Altered peptide ligands (APLs) are synthetic versions of self-antigen peptides with one or a few amino acid substitutions at positions that contact the T cell receptor. These modifications change the quality of TCR signaling, converting what was an inflammatory activation signal into a tolerogenic or regulatory one. The goal is to retrain autoreactive T cells to tolerate rather than attack self-tissue.

How do altered peptide ligands treat autoimmune disease?

APLs work by immune deviation: they shift the T cell response from inflammatory (Th1, producing IFN-gamma) to anti-inflammatory (Th2, producing IL-4 and IL-10). Nicholson et al. (1995) showed that a single amino acid change in a myelin peptide prevented autoimmune encephalomyelitis in mice by inducing regulatory T cells that were cross-reactive with the original disease-causing peptide.

Were altered peptide ligands tested in humans?

Yes. Two phase II clinical trials tested APLs for multiple sclerosis in 2000. The Kappos et al. trial showed that APL therapy induced immune deviation lasting 2-4.5 years. The Bielekova et al. trial was halted when 3 patients developed MS exacerbations linked to APL treatment. These trials demonstrated that APLs can induce lasting tolerance but also carry unpredictable risks.

Why were MS altered peptide ligand trials stopped?

The Bielekova et al. (2000) trial was stopped because the APL activated disease-causing T cells in some patients instead of tolerizing them. The Kappos et al. trial was suspended due to hypersensitivity reactions in 9% of patients. These events showed that predicting individual responses to APLs remains a major challenge because different patients have different T cell repertoires.

What is the difference between APLs and other tolerogenic peptide approaches?

APLs modify the peptide itself to change TCR signaling. Other approaches present unmodified self-peptides in tolerogenic contexts: loaded onto tolerogenic dendritic cells, conjugated to nanoparticles, or bound to MHC molecules. Urbonaviciute et al. (2023) used MHC-peptide complexes to expand regulatory T cells in autoimmune arthritis. All approaches share the goal of antigen-specific tolerance without broad immunosuppression.

Are altered peptide ligands approved for any disease?

No APL product has been approved for any autoimmune disease as of 2026. The clinical trials for MS and type 1 diabetes revealed safety concerns that halted development. The field has shifted toward next-generation platforms (MHC-peptide complexes, peptide-loaded nanoparticles, tolerogenic dendritic cells) that incorporate additional safety controls while building on the APL concept.